

Find a Drug

SEARCH

Advanced Search

Remicade

Professional

Consumer

Drug Description

Indications & Dosage

Side Effects & Drug Interactions

Warnings & Precautions

Overdosage & Contraindications

Clinical Pharmacology

Patient Information

Consumer

Related Drugs

Enbrel

Humira

Health Resources

Ankylosing Spondylitis

Crohn's Disease

Inflammatory Bowel Disease: Intestinal Problems

Juvenile Arthritis (Juvenile Rheumatoid Arthritis)

Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

« previous 1 2 3 4 5 6 7 8 next »

Remicade



Rheumatoid Arthritis Slideshow



Indications & Dosage

FONT SIZE

A A A

INDICATIONS

Rheumatoid Arthritis

REMICADE, in combination with **methotrexate**, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis.

Crohn's Disease

REMICADE is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy (see **BOXED WARNINGS**, **WARNINGS**, and **PRECAUTIONS**, Pediatric Use).

REMICADE is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn's disease.

Ankylosing Spondylitis

REMICADE is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

Psoriatic Arthritis

REMICADE is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis.

Plaque Psoriasis

WebM

RA Hea
Manage


8 Top M

RA and

Liv
W

Health

Win a V
Test yo

Drug News

New Gout Drug Uloric
Coming Soon?

Prescription Drug
Misuse Is Common

ADHD Drugs Not
Harmful to Genetics

[View More >](#)

Search the Medical
Dictionary for Health
Definitions & Medical
Abbreviations



☐ Updated & New
☐ News & Features

Identify Your Drugs:
Use the RxList Pill
Identifier Tool

Add RxList Search to
Your Website

Google Subscribed Links
& RxList

Popular Searches

Adderall

Boniva

Covera-HS

Elavil

Keppra

Macrobid

Penicillin VK

Remeron

REMICADE is indicated for the treatment of adult patients with chronic severe (i.e., extensive and /or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. REMICADE should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician (see **BOXED WARNINGS**, **WARNINGS**, and **PRECAUTIONS**).

Ulcerative Colitis

REMICADE is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.

DOSAGE AND ADMINISTRATION

Rheumatoid Arthritis

The recommended dose of REMICADE is 3 mg/kg given as an intravenous infusion followed with additional similar doses at 2 and 6 weeks after the first infusion then every 8 weeks thereafter. REMICADE should be given in combination with methotrexate. For patients who have an incomplete response, consideration may be given to adjusting the dose up to 10 mg/kg or treating as often as every 4 weeks bearing in mind that risk of serious infections is increased at higher doses (see **ADVERSE REACTIONS**, **Infections**).

Crohn's Disease or Fistulizing Crohn's Disease

The recommended dose of REMICADE is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adults with moderately to severely active Crohn's disease or fistulizing Crohn's disease. For adult patients who respond and then lose their response, consideration may be given to treatment with 10 mg/kg. Patients who do not respond by Week 14 are unlikely to respond with continued dosing and consideration should be given to discontinue REMICADE in these patients.

The recommended dose of REMICADE for children with moderately to severely active Crohn's disease is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks.

Ankylosing Spondylitis

The recommended dose of REMICADE is 5 mg/kg given as an intravenous infusion followed with additional similar doses at 2 and 6 weeks after the first infusion, then every 6 weeks thereafter.

Psoriatic Arthritis

The recommended dose of REMICADE is 5 mg/kg given as an intravenous infusion followed with additional similar doses at 2 and 6 weeks after the first infusion then every 8 weeks thereafter. REMICADE can be used with or

Feature

- ◆ Depre
- ◆ Sneal
- ◆ Copin
- ◆ Skin (
- ◆ Is Yo
- ◆ Quiz:

Treximet

Xyzal

without methotrexate.

Plaque Psoriasis

The recommended dose of REMICADE is 5 mg/kg given as an intravenous infusion, followed by additional doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter.

Ulcerative Colitis

The recommended dose of REMICADE is 5 mg/kg given as an induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of moderately to severely active ulcerative colitis.

Administration Instructions Regarding Infusion Reactions

Adverse effects during administration of REMICADE have included flu-like symptoms, headache, dyspnea, hypotension, transient fever, chills, gastrointestinal symptoms, and skin rashes. Anaphylaxis might occur at any time during REMICADE infusion. Approximately 20% of REMICADE-treated patients in all clinical trials experienced an infusion reaction compared with 10% of placebo-treated patients (see **ADVERSE REACTIONS**, Infusion-related Reactions). Prior to infusion with REMICADE, premedication may be administered at the physician's discretion. Premedication could include antihistamines (anti-H1 +/- anti-H2), acetaminophen and/or corticosteroids.

During infusion, mild to moderate infusion reactions may improve following slowing or suspension of the infusion, and upon resolution of the reaction, reinitiation at a lower infusion rate and/or therapeutic administration of antihistamines, acetaminophen, and/or corticosteroids. For patients that do not tolerate the infusion following these interventions, REMICADE should be discontinued.

During or following infusion, patients that have severe infusion-related hypersensitivity reactions should be discontinued from further REMICADE treatment. The management of severe infusion reactions should be dictated by the signs and symptoms of the reaction. Appropriate personnel and medication should be available to treat anaphylaxis if it occurs.

Preparation and Administration Instructions Use aseptic technique.

REMICADE vials do not contain antibacterial preservatives. Therefore, the vials after reconstitution should be used immediately, not re-entered or stored. The diluent to be used for reconstitution is 10 mL of Sterile Water for Injection, USP. The total dose of the reconstituted product must be further diluted to 250 mL with 0.9% Sodium Chloride Injection, USP. The infusion concentration should range between 0.4 mg/mL and 4 mg/mL. The REMICADE infusion should begin within 3 hours of preparation.

1. Calculate the dose and the number of REMICADE vials needed. Each REMICADE vial contains 100 mg of infliximab. Calculate the total volume of reconstituted REMICADE solution required.
2. Reconstitute each REMICADE vial with 10 mL of Sterile Water for Injection,

USP, using a syringe equipped with a 21-gauge or smaller needle. Remove the flip-top from the vial and wipe the top with an alcohol swab. Insert the syringe needle into the vial through the center of the rubber stopper and direct the stream of Sterile Water for Injection, USP, to the glass wall of the vial. Do not use the vial if the vacuum is not present. Gently swirl the solution by rotating the vial to dissolve the lyophilized powder. Avoid prolonged or vigorous agitation. **DO NOT SHAKE.** Foaming of the solution on reconstitution is not unusual. Allow the reconstituted solution to stand for 5 minutes. The solution should be colorless to light yellow and opalescent, and the solution may develop a few translucent particles as infliximab is a protein. Do not use if opaque particles, discoloration, or other foreign particles are present.

3. Dilute the total volume of the reconstituted REMICADE solution dose to 250 mL with 0.9% Sodium Chloride Injection, USP, by withdrawing a volume of 0.9% Sodium Chloride Injection, USP, equal to the volume of reconstituted REMICADE from the 0.9% Sodium Chloride Injection, USP, 250 mL bottle or bag. Slowly add the total volume of reconstituted REMICADE solution to the 250 mL infusion bottle or bag. Gently mix.
4. The infusion solution must be administered over a period of not less than 2 hours and must use an infusion set with an in-line, sterile, non-pyrogenic, low-protein-binding filter (pore size of 1.2 µm or less). Any unused portion of the infusion solution should not be stored for reuse.
5. No physical biochemical compatibility studies have been conducted to evaluate the co-administration of REMICADE with other agents. REMICADE should not be infused concomitantly in the same intravenous line with other agents.
6. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If visibly opaque particles, discoloration or other foreign particulates are observed, the solution should not be used.

Storage

Store the lyophilized product under refrigeration at 2°C to 8°C (36°F to 46°F). Do not freeze. Do not use beyond the **expiration date**. This product contains no preservative.

HOW SUPPLIED

REMICADE lyophilized concentrate for IV injection is supplied in individually-boxed single-use vials in the following strength:

NDC 57894-030-01

100 mg infliximab in a 20 mL vial

©Centocor, Inc. 2007 Malvern, PA 19355, USA 1-800-457-6399

April 2007

FDA rev date: 4/19/2007

« previous 1 **2** 3 4 5 6 7 8 next »

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription

drugs to the FDA. Visit the [FDA MedWatch](#) website or call 1-800-FDA-1088.

Bookmark this page: [SHARE](#) 



Take Charge of Your RA Treatment

[Learn about an RA Treatment](#)
[Is This RA Treatment Right For You?](#)
[Some Fast Facts](#)



Health Solutions from our sponsors

[ADHD Treatment](#)

[Allergic Asthma Info](#)

[Alzheimer's Questions?](#)

[Arthritis Medicine](#)

[Baby Care Central](#)

[Better Eating](#)

[Caring for Memory Loss](#)

[Dental Health Guide](#)

[Depression Med for You?](#)

[High Blood Pressure?](#)

[High Cholesterol?](#)

[Living with Knee Pain](#)

[Lower Cholesterol](#)

[Managing Depression](#)

[Menopausal Symptoms?](#)

[Overactive Bladder Rx](#)

[RxList Home](#) | [Drugs & Medications A-Z List](#) | [Picture Slideshows](#) | [Pill Identification Tool](#) | [Diseases & Conditions](#) | [Drug Medical Dicti](#)
[About RxList](#) | [Professional Drug Submission Form](#) | [Consumer Contact RxList](#) | [Terms & Conditions](#) | [Privacy Policy](#) | [Sponsor Policy](#) |
[WebMD®](#) | [MedScape®](#) | [eMedicineHealth®](#) | [MedicineNet®](#)

Copyright © 2008 by RxList Inc.

RxList does not provide medical advice, diagnosis or treatment. See additional information.